Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084799 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC)
A Phase 1 study, sponsored by Ludwig Institute for Cancer Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00084799 is a Phase 1 study that has completed, run by Ludwig Institute for Cancer Research. The registered enrollment target is 10 participants.
The verdict
NCT00084799, a Phase 1 study, has completed, sponsored by Ludwig Institute for Cancer Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: This phase I trial is studying the side effects of monoclonal antibody therapy in treating patients with progressive small cell lung cancer (SCLC).
Interventions
- BIOLOGICAL monoclonal antibody hu3S193
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2004-07-26 |
| Est. Completion | 2006-12-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00084799
The ClinicalTrials.gov registry entry for NCT00084799 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ludwig Institute for Cancer Research, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which monoclonal antibody hu3S193 is the first listed.
NCT00084799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00084799 about?
NCT00084799 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC)". RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: This phase I trial is studying the side effects of monoclonal antibody therapy in treating patients with progressive small cell lung cancer...
What is the current status of trial NCT00084799?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2004-07-26. Estimated completion is 2006-12-20.
What interventions are being tested in trial NCT00084799?
The interventions under investigation include: monoclonal antibody hu3S193 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00084799?
This trial is sponsored by Ludwig Institute for Cancer Research, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.